Incyte
NEWS
Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories.
The investigational JAK inhibitor has hit the mark in three late-stage studies, with readouts from two more late-stage trials expected later this year.
With more than 16,000 attendees from 67 countries and hundreds, even thousands of presentations, it can be difficult to get a real grip on everything that went on at the 2019 BIO International Convention held in Philadelphia. Here’s a look at just a few of the highlights.
The approval of Jakafi marks the first approved treatment for this indication in the United States.
May has been a fairly slow month for approvals by the U.S. Food and Drug Administration (FDA). There are currently only two scheduled for the rest of the month, with a third that has been withdrawn. Let’s take a look.
For young people looking to find a career path, the pharmaceutical industry is a good one to go into, especially if salary is a major concern.
Two of the three drugs that were up for review in mid- to late-February received much earlier approval in December 21, the day before the federal government shutdown. The shutdown ended on January 25, 2019.
The two Phase III trials are part of a five-trial package the companies are conducting to support potential regulatory approval for this indication.
The American Society of Hematology is holding its 60th Annual Meeting & Exposition starting December 1 and running through December 4 in San Diego. Most of the players, big and small, in cancer drug therapies will be there, presenting updates and breaking stories about their hematology pipelines.
JOBS
IN THE PRESS